Among 100 consecutive patients receiving heparin in therapeutic dosage, major bleeding occurred in 21, and minor bleeding in 16. Two patients died from bleeding, and two had recurrent pulmonary embolism. Major bleeding occurred in 21% when therapy was regulated with whole-blood clotting time and in 20% when heparin was given without clotting tests. In a subsequent prospective trial patients received heparin by intermittent intravenous injection with or without laboratory control according to the partial thromboplastin time or continuously by intravenous infusion. Recurrent thromboembolism occurred once in each group. Major bleeding was seven times more frequent with intermittent injection than with continuous infusion. Control with the partial thromboplastin time did not prevent major bleeding in patients receiving intermittent injections. With continuous infusion, one-fourth less heparin was required than with intermittent injections. Administration of heparin by continuous infusion appears safer than intermittent injection with or without laboratory control and is no less effective for prevention of thromboembolism.
This article has been cited by other articles:
Schulman, S., Beyth, R. J., Kearon, C., Levine, M. N.
(2008). Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 257S-298S
[Abstract][Full Text]
Carson, J. L.
(2006). Subcutaneous unfractionated heparin vs low-molecular-weight heparin for acute thromboembolic disease: issues of efficacy and cost.. JAMA
296: 991-993
[Full Text]
Ascher, E., DePippo, P. S., Hingorani, A., Yorkovich, W., Salles-Cunha, S.
(2004). Does Repeat Duplex Ultrasound for Lower Extremity Deep Vein Thrombosis Influence Patient Management?. VASC ENDOVASCULAR SURG
38: 525-531
[Abstract]
Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C., Schulman, S.
(2004). Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest
126: 287S-310S
[Abstract][Full Text]
Buller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., Raskob, G. E.
(2004). Antithrombotic Therapy for Venous Thromboembolic Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest
126: 401S-428S
[Abstract][Full Text]
Hyers, T. M.
(2003). Management of Venous Thromboembolism: Past, Present, and Future. Arch Intern Med
163: 759-768
[Abstract][Full Text]
Hadlock, T. A., Kim, J., Deschler, D. G.
(2003). The Effect of Subcutaneously Administered Low-Molecular-Weight Heparin on Microarterial Thrombosis in the Rat. Arch Facial Plast Surg
5: 36-39
[Abstract][Full Text]
Hirsh, J., Anand, S. S., Halperin, J. L., Fuster, V.
(2001). Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association. Arterioscler. Thromb. Vasc. Bio.
21
: e9-e9
[Full Text]
Hirsh, J., Anand, S. S., Halperin, J. L., Fuster, V.
(2001). Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association. Circulation
103: 2994-3018
[Full Text]
Breddin, H. K., Hach-Wunderle, V., Nakov, R., Kakkar, V. V., The CORTES Investigators,
(2001). Effects of a Low-Molecular-Weight Heparin on Thrombus Regression and Recurrent Thromboembolism in Patients with Deep-Vein Thrombosis. NEJM
344: 626-631
[Abstract][Full Text]
Hirsh, J., Warkentin, T. E., Shaughnessy, S. G., Anand, S. S., Halperin, J. L., Raschke, R., Granger, C., Ohman, E. M., Dalen, J. E.
(2001). Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. Chest
119
: 64S-94S
[Full Text]
Levine, M. N., Raskob, G., Landefeld, S., Kearon, C.
(2001). Hemorrhagic Complications of Anticoagulant Treatment. Chest
119
: 108S-121S
[Full Text]
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., Weg, J. G.
(2001). Antithrombotic Therapy for Venous Thromboembolic Disease. Chest
119
: 176S-193S
[Full Text]
Zidane, M., Schram, M. T., Planken, E. W., Molendijk, W. H., Rosendaal, F. R., van der Meer, F. J. M., Huisman, M. V.
(2000). Frequency of Major Hemorrhage in Patients Treated With Unfractionated Intravenous Heparin for Deep Venous Thrombosis or Pulmonary Embolism: A Study in Routine Clinical Practice. Arch Intern Med
160: 2369-2373
[Abstract][Full Text]
Hull, R. D., Raskob, G. E., Brant, R. F., Pineo, G. F., Elliott, G., Stein, P. D., Gottschalk, A., Valentine, K. A., Mah, A. F., for the American-Canadian Thrombosis Study Group,
(2000). Low-Molecular-Weight Heparin vs Heparin in the Treatment of Patients With Pulmonary Embolism. Arch Intern Med
160: 229-236
[Abstract][Full Text]
Bick, R. L., Frenkel, E. P.
(1999). Clinical Aspects of Heparin-Induced Thrombocytopenia and Thrombosis and Other Side Effects of Heparin Therapy. CLIN APPL THROMB HEMOST
5: S7-S15
[Abstract]
LAWTON, R. L., MORREY, B. F.
(1999). The Use of Heparin in Patients in Whom a Pulmonary Embolism is Suspected After Total Hip Arthroplasty. JBJS
81: 1063-72
[Abstract][Full Text]
Ameer, G. A., Barabino, G., Sasisekharan, R., Harmon, W., Cooney, C. L., Langer, R.
(1999). Ex vivo evaluation of a Taylor-Couette flow, immobilized heparinase I device for clinical application. Proc. Natl. Acad. Sci. USA
96: 2350-2355
[Abstract][Full Text]
Kahn, S. R.
(1998). The Clinical Diagnosis of Deep Venous Thrombosis: Integrating Incidence, Risk Factors, and Symptoms and Signs. Arch Intern Med
158: 2315-2323
[Abstract][Full Text]
Rachakonda, V., Rachakonda, L., Belliveau, R. R.
(1998). aPTT in Heparinized Patients: Influence of the Interval Between Sampling and Testing. CLIN APPL THROMB HEMOST
4: 213-216
[Abstract]
Valentine, K. A., Hull, R. D., Pineo, G. F.
(1998). Low-Molecular-Weight Heparin Therapy and Mortality. PERSPECT VASC SURG ENDOVASC THER
9: 99-108
[Abstract]
Hull, R. D., Raskob, G. E., Brant, R. F., Pineo, G. F., Valentine, K. A.
(1997). Relation Between the Time to Achieve the Lower Limit of the APTT Therapeutic Range and Recurrent Venous Thromboembolism During Heparin Treatment for Deep Vein Thrombosis. Arch Intern Med
157: 2562-2568
[Abstract]
Hull, R. D., Raskob, G. E., Brant, R. F., Pineo, G. F., Valentine, K. A.
(1997). The Importance of Initial Heparin Treatment on Long-term Clinical Outcomes of Antithrombotic Therapy: The Emerging Theme of Delayed Recurrence. Arch Intern Med
157: 2317-2321
[Abstract]
Hull, R. D., Raskob, G. E., Rosenbloom, D., Pineo, G. F., Lerner, R. G., Gafni, A., Trowbridge, A. A., Elliott, C. G., Green, D., Feinglass, J., Feldstein, W., Brant, R.
(1997). Treatment of Proximal Vein Thrombosis With Subcutaneous Low-Molecular-Weight Heparin vs Intravenous Heparin: An Economic Perspective. Arch Intern Med
157: 289-294
[Abstract]
Schwarz, R. P. JR, Becker, J.-C. P., Brooks, R. L., Hursting, M. J., Joffrion, J. L., Knappenberger, G. D., Kogan, T. P., Kogan, P. W., McKinney, A. A.
(1997). State-of-the-Art Review: The Preclinical and Clinical Pharmacology of Novastan (Argatroban): A Small-Molecule, Direct Thrombin Inhibitor. CLIN APPL THROMB HEMOST
3: 1-15
[Abstract]
Anand, S., Ginsberg, J. S., Kearon, C., Gent, M., Hirsh, J.
(1996). The Relation Between the Activated Partial Thromboplastin Time Response and Recurrence in Patients With Venous Thrombosis Treated With Continuous Intravenous Heparin. Arch Intern Med
156: 1677-1681
[Abstract]
Hirsh, J., Hoak, J.
(1996). Management of Deep Vein Thrombosis and Pulmonary Embolism : A Statement for Healthcare Professionals From the Council on Thrombosis (in Consultation With the Council on Cardiovascular Radiology), American Heart Association. Circulation
93: 2212-2245
[Full Text]
Campbell, N. R. C., Hull, R. D., Brant, R., Hogan, D. B., Pineo, G. F., Raskob, G. E.
(1996). Aging and Heparin-Related Bleeding. Arch Intern Med
156: 857-860
[Abstract]
Gunnarsson, P. S., Sawyer, W. T., Montague, D., Williams, M. L., Dupuis, R. E., Caiola, S. M.
(1995). Appropriate Use of Heparin: Empiric vs Nomogram-Based Dosing. Arch Intern Med
155: 526-532
[Abstract]
Hull, R. D., Raskob, G. E., Pineo, G. F., Brant, R. F.
(1995). The Treatment of Proximal Vein Thrombosis with Subcutaneous Low-Mole Molecular-Weight Heparin Compared with Continuous Intravenous Heparin. CLIN APPL THROMB HEMOST
1: 151-159
[Abstract]
Weinmann, E. E., Salzman, E. W.
(1994). Deep-Vein Thrombosis. NEJM
331: 1630-1641
[Full Text]
O'Meara, J. J., McNutt, R. A., Evans, A. T., Moore, S. W., Downs, S. M.
(1994). A Decision Analysis of Streptokinase plus Heparin as Compared with Heparin Alone for Deep-Vein Thrombosis. NEJM
330: 1864-1869
[Abstract][Full Text]
Carr, J. M., Horowitz, G., O'Reilly, R. A., Kearns, P. J., Schuff-Werner, P., Schutz, E., Gonska, B.-D., Eckman, M. H., Levine, H. J., Pauker, S. G.
(1994). Variation in the Prothrombin-Time Ratio during Oral Anticoagulation. NEJM
330: 509-510
[Full Text]
Landefeld, C. S., Anderson, P. A.
(1992). Guideline-based Consultation To Prevent Anticoagulant-related Bleeding: A Randomized, Controlled Trial in a Teaching Hospital. ANN INTERN MED
116: 829-837
[Abstract]
Foster, P. F., Moore, L. R., Sankary, H. N., Hart, M. E., Ashmann, M. K., Williams, J. W.
(1992). Central Venous Catheterization in Patients With Coagulopathy. Arch Surg
127: 273-275
[Abstract]
Hommes, D. W., Bura, A., Mazzolai, L., Buller, H. R., ten Cate, J. W.
(1992). Subcutaneous Heparin Compared with Continuous Intravenous Heparin Administration in the Initial Treatment of Deep Vein Thrombosis: A Meta-analysis. ANN INTERN MED
116: 279-284
[Abstract]
Seed, W.
(1991). Pulmonary embolism: Part 1. Vasc Med
2: 71-83
Cruickshank, M. K., Levine, M. N., Hirsh, J., Roberts, R., Siguenza, M.
(1991). A Standard Heparin Nomogram for the Management of Heparin Therapy. Arch Intern Med
151: 333-337
[Abstract]
Wheeler, A. P., Jaquiss, R. D. B., Newman, J. H.
(1988). Physician Practices in the Treatment of Pulmonary Embolism and Deep Venous Thrombosis. Arch Intern Med
148: 1321-1325
[Abstract]
Rosiello, R. A., Chan, C. K., Tencza, F., Matthay, R. A.
(1987). Timing of Oral Anticoagulation Therapy in the Treatment of Angiographically Proven Acute Pulmonary Embolism. Arch Intern Med
147: 1469-1473
[Abstract]
Lutomski, D. M., Djuric, P. E., Draeger, R. W.
(1987). Warfarin Therapy: The Effect of Heparin on Prothrombin Times. Arch Intern Med
147: 432-433
[Abstract]
SUCHMAN, A. L., GRINER, P. F.
(1986). Diagnostic Decision: Diagnostic Uses of the Activated Partial Thromboplastin Time and Prothrombin Time. ANN INTERN MED
104: 810-816
[Abstract]
Kaplan, K.
(1986). Prophylactic Anticoagulation Following Acute Myocardial Infarction. Arch Intern Med
146: 593-597
[Abstract]
Almazan, A., Lozano, F., Ramos, M., Rodriguez-Moran, M., Gomez-Alonso, A.
(1985). Laboratory Control of Continuous Intravenous Heparin Therapy with Howel Time and Activated Partial Thromboplastin Time A Prospective, Randomized and Blind Study. ANGIOLOGY
36: 363-369
[Abstract]
(1984). Implantable and External Infusion Pumps for the Treatment of Thromboembolic Disease in Outpatients. ANN INTERN MED
100: 305-306
[Abstract]
Hattersley, P. G., Mitsuoka, J. C., King, J. H.
(1983). Heparin Therapy for Thromboembolic Disorders: A Prospective Evaluation of 134 Cases Monitored by the Activated Coagulation Time. JAMA
250: 1413-1416
[Abstract]
Sasahara, A. A., Sharma, G. V. R. K., Barsamian, E. M., Schoolman, M., Cella, G.
(1983). Pulmonary Thromboembolism: Diagnosis and Treatment. JAMA
249: 2945-2950
[Abstract]
Almazan, A., Lozano, F., Ramos, M., Gomez-Alonso, A.
(1983). Control and Management of Heparin Therapy in Venous Thromboembolism. VASC ENDOVASCULAR SURG
17: 1-8
Coon, W. W.
(1982). Management of Anticoagulant and Thrombolytic Agents in Deep Venous Thrombosis. VASC ENDOVASCULAR SURG
16: 1-7
Collins, G. J. Jr, Rich, N. M., Clagett, G. P., Spebar, M. J., Salander, J. M.
(1981). Heparin: Efficacy and Safety After Arterial Operations. Arch Surg
116: 1077-1081
[Abstract]
Salberg, D. J.
(1981). Pulmonary Thromboembolism -- Update. JAMA
245: 2295-2295
[Abstract]
Walker, A. M., Jick, H.
(1980). Predictors of Bleeding During Heparin Therapy. JAMA
244: 1209-1212
[Abstract]
Spaet, T. H.
(1980). Heparin Therapy. JAMA
244: 1243-1243
[Abstract]
Hattersley, P. G., Mitsuoka, J. C., King, J. H.
(1980). Sources of Error in Heparin Therapy of Thromboembolic Disease. Arch Intern Med
140: 1173-1175
[Abstract]
Bivins, B. A., Rapp, R. P., Powers, P., Butler, J. L., Haack, D.
(1980). Electronic Flow Control and Roller Clamp Control in Intravenous Therapy: A Clinical Comparison. Arch Surg
115: 70-72
[Abstract]
Korwin, S. M., Callow, A. D., Rosenthal, D., Ledig, C. B., Deterling, R. A. Jr, O'Donnell, T. F. Jr
(1979). Prophylactic Interruption of the Inferior Vena Cava: Immediate and Long-term Hemodynamic Effects. Arch Surg
114: 1037-1040
[Abstract]
Duffy, T. P.
(1979). Heparin-Induced Thrombocytopenia. JAMA
241: 2424-2424
[Abstract]
Thomas, J. L., Cunningham, J. J.
(1978). Echographic Detection and Characterization of Abdominal Hemorrhages: In Patients With Altered Coagulation States. Arch Intern Med
138: 1392-1393
[Abstract]
Hume, M.
(1977). Standard Management of Venous Thrombosis. VASC ENDOVASCULAR SURG
11: 197-200
Kerstein, M. D.
(1977). Thrombophlebitis. ANGIOLOGY
28: 228-234
BELL, W. R., TOMASULO, P. A., ALVING, B. M., DUFFY, T. P.
(1976). Thrombocytopenia Occurring During the Administration of Heparin: A Prospective Study in 52 Patients. ANN INTERN MED
85: 155-160
[Abstract]
(1976). Pulmonary Disease: An Annotated Bibliography of Recent Literature: References to Journal Articles and Other Papers. ANN INTERN MED
85: 135-139
[Abstract]
CAPRINI, J. A.
(1976). Hazards of Heparin Therapy. Arch Surg
111: 615-615
[Abstract]
ARIYAN, S., STANSEL, H. C. JR
(1976). Hazards of Heparin Therapy-Reply. Arch Surg
111: 615-615
[Abstract]
Previous
